Syntara Limited has released a press release.
Pharmaxis Prioritises Clinical Program on Myelofibrosis
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Syntara
- September Quarter 2020 Activity Report
- Boehringer Ingelheim discontinues development of BI 1467335
- Pharmaxis Awarded $1M Australian Government Grant
- FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
- US$7 million Bronchitol Launch Milestone Brought Forward
Later from Syntara
- Pharmaxis Receives US$7m milestone from Chiesi
- Quarterly Activity Report - December 2020
- Pharmaxis Exports CF Drug to US - US$3 Million Milestone
- First Patient Enrolled - Clinical Trial for Cancer Treatment
- Sale of Russian Distribution Rights
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara